Abstract
Functional inactivation of transcription factors in hematopoietic stem cell development is involved in the pathogenesis of acute myeloid leukemia (AML). Stem cell regulator C/enhancer binding protein (EBP)α is among such transcription factors known to be inactive in AML. This is either due to mutations or inhibition by protein–protein interactions. Here, we applied a mass spectrometry-based proteomic approach to systematically identify putative co-activator proteins interacting with the DNA-binding domain (DBD) of C/EBP transcription factors. In our proteomic screen, we identified c-Jun N-terminal kinase (JNK) 1 among others such as PAK6, MADP-1, calmodulin-like skin proteins and ZNF45 as proteins interacting with DBD of C/EBPs from nuclear extract of myelomonocytic U937 cells. We show that kinase JNK1 physically interacts with DBD of C/EBPα in vitro and in vivo. Furthermore, we show that active JNK1 inhibits ubiquitination of C/EBPα possibly by phosphorylating in its DBD. Consequently, JNK1 prolongs C/EBPα protein half-life leading to its enhanced transactivation and DNA-binding capacity. In certain AML patients, however, the JNK1 mRNA expression and its kinase activity is decreased which suggests a possible reason for C/EBPα inactivation in AML. Thus, we report the first proteomic screen of C/EBP-interacting proteins, which identifies JNK1 as positive regulator of C/EBPα.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Balkhi MY, Trivedi AK, Geletu M, Christopeit M, Bohlander SK, Behre HM et al. (2006). Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene May 29: [Epub ahead of print].
Behre G, Reddy VA, Tenen DG, Hiddemann W, Zada AA, Singh SM . (2002a). Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia. Expert Opin Ther Targets 6: 491–495.
Behre G, Singh SM, Liu H, Bortolin LT, Christopeit M, Radomska HS et al. (2002b). Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248. J Biol Chem 277: 26293–26299.
Bogoyevitch MA, Ketterman AJ, Sugden PH . (1995). Cellular stresses differentially activate c-Jun N-terminal protein kinases and extracellular signal-regulated protein kinases in cultured ventricular myocytes. J Biol Chem 270: 29710–29717.
Cleaves R, Wang QF, Friedman AD . (2004). C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding. Oncogene 23: 716–725.
Cristea IM, Gaskell SJ, Whetton AD . (2004). Proteomics techniques and their application to hematology. Blood 103: 3624–3634.
D’Alo F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P et al. (2003). The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. Blood 102: 3163–3171.
Friedman AD . (1996). GADD153/CHOP, a DNA damage-inducible protein, reduced CAAT/enhancer binding protein activities and increased apoptosis in 32D c13 myeloid cells. Cancer Res 56: 3250–3256.
Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al. (2004). CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22: 624–633.
Fuchs SY, Dolan L, Davis RJ, Ronai Z . (1996). Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 13: 1531–1535.
Fuchs SY, Fried VA, Ronai Z . (1998). Stress-activated kinases regulate protein stability. Oncogene 17: 1483–1490.
Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ, Ronai Z . (1997). c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J Biol Chem 272: 32163–32168.
Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH et al. (2002). Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99: 1332–1340.
Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L et al. (2001). c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108: 73–81.
Hattori T, Ohoka N, Inoue Y, Hayashi H, Onozaki K . (2003). C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer. Oncogene 22: 1273–1280.
Iakova P, Awad SS, Timchenko NA . (2003). Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 113: 495–506.
Kyriakis JM, Avruch J . (1990). pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J Biol Chem 265: 17355–17363.
Landschulz WH, Johnson PF, McKnight SL . (1989). The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite. Science 243: 1681–1688.
Mahoney CW, Shuman J, McKnight SL, Chen HC, Huang KP . (1992). Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding. J Biol Chem 267: 19396–19403.
Mann M, Hendrickson RC, Pandey A . (2001). Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 70: 437–473.
Moriguchi T, Toyoshima F, Masuyama N, Hanafusa H, Gotoh Y, Nishida E . (1997). A novel SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses. EMBO J 16: 7045–7053.
Morton S, Davis RJ, McLaren A, Cohen P . (2003). A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 22: 3876–3886.
Muller C, Calkhoven CF, Sha X, Leutz A . (2004). The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest. J Biol Chem 279: 7353–7358.
Muller C, Kowenz-Leutz E, Grieser-Ade S, Graf T, Leutz A . (1995). NF-M (chicken C/EBP beta) induces eosinophilic differentiation and apoptosis in a hematopoietic progenitor cell line. EMBO J 14: 6127–6135.
Musti AM, Treier M, Bohmann D . (1997). Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275: 400–402.
Nordeen SK . (1988). Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques 6: 454–458.
Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. (2001a). AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7: 444–451.
Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. (2001b). Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27: 263–270.
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. (2002). BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30: 48–58.
Perrotti D, Marcucci G, Caligiuri MA . (2004). Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. J Clin Oncol 22: 582–584.
Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis-Hansen L et al. (2001). E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell 107: 247–258.
Raitano AB, Halpern JR, Hambuch TM, Sawyers CL . (1995). The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92: 11746–11750.
Rangatia J, Vangala RK, Treiber N, Zhang P, Radomska H, Tenen DG et al. (2002). Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment. Mol Cell Biol 22: 8681–8694.
Reddy VA, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK et al. (2002). Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood 100: 483–490.
Ronai Z . (2004). JNKing Revealed. Mol Cell 15: 843–844.
Ross SE, Erickson RL, Hemati N, MacDougald OA . (1999). Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 19: 8433–8441.
Ross SE, Radomska HS, Wu B, Zhang P, Winnay JN, Bajnok L et al. (2004). Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol 24: 675–686.
Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S et al. (2002). Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 99: 10008–10013.
Scott LM, Civin CI, Rorth P, Friedman AD . (1992). A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 80: 1725–1735.
Shim M, Smart RC . (2003). Lithium stabilizes the CCAAT/enhancer-binding protein alpha (C/EBPalpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity. J Biol Chem 278: 19674–19681.
Sieweke MH, Graf T . (1998). A transcription factor party during blood cell differentiation. Curr Opin Genet Dev 8: 545–551.
Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J . (2004). Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351: 2403–2407.
Subramanian L, Benson MD, Iniguez-Lluhi JA . (2003). A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J Biol Chem 278: 9134–9141.
Tenen DG . (2003). Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3: 89–101.
Terrance A Stadheim GLK . (2002). c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leukemia Res 26: 55–65.
Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG et al. (2003). The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101: 270–277.
Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ et al. (2001). C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 8: 817–828.
Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW . (1998). The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 18: 322–333.
Xu S, Cobb MH . (1997). MEKK1 binds directly to the c-Jun N-terminal kinases/stress-activated protein kinases. J Biol Chem 272: 32056–32060.
Yoon K, Smart RC . (2004). C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol 24: 10650–10660.
Zada AA, Singh SM, Reddy VA, Elsasser A, Meisel A, Haferlach T et al. (2003). Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 22: 2296–2308.
Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG . (1997). Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94: 569–574.
Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D . (2004). Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 103: 1883–1890.
Acknowledgements
We thank Dr Roger Davis for providing pCDNA3-MKK7, pCDNA3-MEKK1-flag; Dr Daniel G Tenen and Dr Claus Nerlov for GST, GST-DBD and GST-C/EBPα expressin plasmids. This work was supported by Deutsche José Carreras Leukamie-Stiftung e.V. grant, DJCLS F03/03 to Dr Trivedi AK.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Trivedi, A., Bararia, D., Christopeit, M. et al. Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPα by inhibiting its ubiquitination. Oncogene 26, 1789–1801 (2007). https://doi.org/10.1038/sj.onc.1209964
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209964
Keywords
This article is cited by
-
CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia
Medical Oncology (2021)
-
Up-regulation of interferon-stimulated gene 15 and its conjugation machinery, UbE1L and UbcH8 expression by tumor necrosis factor-α through p38 MAPK and JNK signaling pathways in human lung carcinoma
Molecular and Cellular Biochemistry (2019)
-
Further dissection of QTLs for salt-induced stroke and identification of candidate genes in the stroke-prone spontaneously hypertensive rat
Scientific Reports (2018)
-
Acetylation of C/EBPα inhibits its granulopoietic function
Nature Communications (2016)
-
The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia
Oncogene (2016)